DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Arcadia Investment Management Corp MI

Arcadia Investment Management Corp MI trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 19.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 15,105 shares of the medical device company's stock after selling 3,585 shares during the period. Arcadia Investment Management Corp MI's holdings in DexCom were worth $1,032,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Norges Bank bought a new stake in DexCom during the 4th quarter worth approximately $385,367,000. Woodline Partners LP bought a new position in shares of DexCom in the fourth quarter worth about $63,338,000. Northern Trust Corp grew its position in shares of DexCom by 22.2% during the fourth quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock worth $322,454,000 after purchasing an additional 753,857 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in DexCom during the 4th quarter valued at approximately $41,295,000. Finally, GAMMA Investing LLC lifted its holdings in DexCom by 5,951.7% in the 1st quarter. GAMMA Investing LLC now owns 499,746 shares of the medical device company's stock worth $34,128,000 after purchasing an additional 491,488 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of research reports. Canaccord Genuity Group lifted their price target on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Citigroup restated a "buy" rating and set a $102.00 price target (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Cfra Research upgraded shares of DexCom to a "hold" rating in a report on Friday, March 21st. Wall Street Zen cut shares of DexCom from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Finally, Truist Financial assumed coverage on DexCom in a research note on Monday, June 16th. They set a "buy" rating and a $102.00 price objective for the company. Five analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $98.50.

Insider Buying and Selling at DexCom

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of the firm's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $83.13, for a total transaction of $228,607.50. Following the transaction, the director directly owned 56,621 shares of the company's stock, valued at approximately $4,706,903.73. This trade represents a 4.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Sadie Stern sold 6,184 shares of DexCom stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the transaction, the executive vice president owned 109,621 shares in the company, valued at $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 27,190 shares of company stock worth $2,281,732. 0.32% of the stock is currently owned by corporate insiders.

DexCom Price Performance

Shares of NASDAQ DXCM traded down $2.09 during trading on Friday, hitting $83.37. The company had a trading volume of 2,309,390 shares, compared to its average volume of 4,415,593. The firm has a market capitalization of $32.69 billion, a price-to-earnings ratio of 62.22, a price-to-earnings-growth ratio of 1.81 and a beta of 1.44. The stock has a fifty day simple moving average of $84.31 and a two-hundred day simple moving average of $79.97. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $117.19.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. The firm's revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.32 EPS. On average, research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.